同时化学放射治疗的生存益处对于晚期的阿姆普拉的父亲癌症
Chae Hwa Kwon1, Hyung Il Seo2, Dong Uk Kim3
1BioMedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
辅助性并发化疗放射治疗 (CCRT) 没有改善切除瘤囊的患者的存活率. 需要进一步的研究来确定这种情况的标准辅助疗法.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 腹膜癌 (AoV) 癌症在切除后缺乏标准的辅助疗法.
- 先进的AoV癌症是一个重大的临床挑战.
研究的目的:
- 评估辅助性并发化疗放射治疗 (CCRT) 在晚期AoV癌症治疗后切除患者的疗效.
- 为了确定CCRT是否改善了这一患者群的生存结果.
主要方法:
- 对29名患有晚期AoV癌症,接受胰腺二切除术 (2006-2018) 的患者的回顾性分析.
- 评估无复发生存率 (RFS) 和整体生存率 (OS).
- 风险因素的分析,包括淋巴血管侵袭,T阶段和淋巴结转移.
主要成果:
- 一年,三年和五年RFS率分别为82.8%,48.3%和40.8%;OS率分别为89.7%,62.1%和51.7%.
- 与没有CCRT相比,辅助CCRT没有显著改善RFS或OS.
- 淋巴血管侵袭,T阶段和淋巴结转移是显著的预后因素.
结论:
- 辅助性CCRT并不能提高晚期切除AOV癌症患者的生存结果.
- 结果为临床决策提供了有关辅助治疗策略的见解.
- 强调需要为AOV癌症开发标准化辅助疗法.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cancer Survival Analysis
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
